Clinical Trials Logo

Clinical Trial Summary

The project is a randomized, 2-way, blinded parallel trial in which 56 healthy adults of both genders with frequent occurrence of stomach trouble.This intervention trial with 6 weeks of daily intake β-glucans will be carried out with a beverage containing β-glucans and a control beverage without β-glucans. The primary aim is to investigate whether β-glucans from barley has an effect on stomach and intestinal health, including stool volume and frequency. Microbiota, concentrations of short chain fatty acids (butyrate, propionate, acetate), calprotectin, and energy and fat content in feces. Furthermore, blood pressure and exhaled hydrogen and methane, before and after the intervention, subjective perception of gastrointestinal problems and digestion as well as the participants' attitudes towards functional foods are measured using Visual Analog Scale (VAS).

Further, specific metabolites of β-glucans in urine (exploratory endpoint) and certain toxic metabolites from the microbiota using metabolite profiling (metabolomics) are also analyzed


Clinical Trial Description

β-glucans from barley slows gastric emptying rate and prolongs the transit time of food in the small intestine." The relatively undigested β-glucans have the ability to increase satiety and stimulate digestion, ensuring regular bowel movements and relieve sluggish bowel movements, including constipation and constipation. β-glucans are fermented down in the large intestine, resulting in production of short-chain fatty acids which inhibit the biosynthesis of cholesterol, hence blood cholesterol levels are lowered (not the goal here). Subsequently, β-glucans may also affect blood pressure. As a direct result of the effects in the intestine, there will be an improvement in the quality of life for people with stomach upsets and maybe a reduction in the risk of cardiovascular disease. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03046667
Study type Interventional
Source University of Copenhagen
Contact
Status Completed
Phase N/A
Start date February 8, 2017
Completion date December 11, 2017

See also
  Status Clinical Trial Phase
Completed NCT05619341 - Effect of Rate Of Delivery on Colonic Fermentation of inuliN (EON) N/A
Completed NCT05811663 - Health Care Use and Costs of Functional Somatic Disorders
Completed NCT06006715 - Psychiatric Disorders and Functional Somatic Disorders
Enrolling by invitation NCT04011943 - Fecal Microbiota Transplantation for Health Improvement (TFM3) N/A
Completed NCT04245254 - GutMe!: IBS and Collagen Protein Powder an Interventional Study N/A
Recruiting NCT04214470 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
Completed NCT02742597 - Patient-Centred Innovations for Persons With Multimorbidity - Ontario N/A
Active, not recruiting NCT05463900 - Microbial and Human Determinants of the Onset of IBD Flares
Completed NCT02789800 - Patient-Centred Innovations for Persons With Multimorbidity - Quebec N/A